Literature DB >> 32032554

Peripheral microRNA panels to guide the diagnosis of familial cardiomyopathy.

Thalía Belmonte1, Alipio Mangas2, Maria Calderon-Dominguez1, Maribel Quezada-Feijoo3, Monica Ramos3, Oscar Campuzano4, Silvia Gomez5, Maria Luisa Peña5, Andres M Cubillos-Arango6, Fernando Dominguez7, Vicenta Llorente-Cortés8, David de Gonzalo-Calvo9, Rocio Toro10.   

Abstract

Etiology-based diagnosis of dilated cardiomyopathy (DCM) is challenging. We evaluated whether peripheral microRNAs (miRNAs) could be used to characterize the DCM etiology. We investigated the miRNA plasma profiles of 254 subjects that comprised 5 groups: Healthy subjects (n = 70), idiopathic DCM patients (n = 55), ischemic DCM patients (n = 60) and 2 groups of patients with pathogenic variants responsible for familial DCM in the LMNA (LMNAMUT, n = 37) and BAG3 (BAG3MUT, n = 32) genes. Diagnostic performance was assessed using receiver operating characteristic curves. In a screening study (n = 30), 179 miRNAs robustly detected in plasma samples were profiled in idiopathic DCM and carriers of pathogenic variants. After filtering, 26 miRNA candidates were selected for subsequent quantification in the whole study population. In the validation study, a 6-miRNA panel identified familial DCM with an AUC (95% confidence interval [CI]) of 87.8 (82.0-93.6). The 6-miRNA panel also distinguished between specific DCM etiologies with AUCs ranging from 85.9 to 89.9. Only 1 to 10 of the subjects in the first and second tertiles of the 6-miRNA panel were patients with familial DCM. Additionally, a 5-miRNA panel showed an AUC (95% CI) of 87.5 (80.4-94.6) for the identification of carriers with pathogenic variants who were phenotypically negative for DCM. The 5-miRNA panel discriminated between carriers and healthy controls with AUCs ranging from 83.2 to 90.8. Again, only 1 to 10 of the subjects in the lowest tertiles of the 5-miRNA panel were carriers of pathogenic variants. In conclusion, miRNA signatures could be used to rule out patients with pathogenic variants responsible for DCM.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32032554     DOI: 10.1016/j.trsl.2020.01.003

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  8 in total

Review 1.  Peripheral blood microRNAs and the COVID-19 patient: methodological considerations, technical challenges and practice points.

Authors:  Lucía Pinilla; Ivan D Benitez; Jessica González; Gerard Torres; Ferran Barbé; David de Gonzalo-Calvo
Journal:  RNA Biol       Date:  2021-02-15       Impact factor: 4.652

2.  Plasma microrna expression profile for reduced ejection fraction in dilated cardiomyopathy.

Authors:  Maria Calderon-Dominguez; Thalía Belmonte; Maribel Quezada-Feijoo; Mónica Ramos; Juan Calderon-Dominguez; Oscar Campuzano; Alipio Mangas; Rocio Toro
Journal:  Sci Rep       Date:  2021-04-06       Impact factor: 4.379

3.  Circulating circRNA as biomarkers for dilated cardiomyopathy etiology.

Authors:  Marina C Costa; Maria Calderon-Dominguez; Alipio Mangas; Oscar Campuzano; Georgia Sarquella-Brugada; Mónica Ramos; Maribel Quezada-Feijoo; José Manuel García Pinilla; Ainhoa Robles-Mezcua; Galan Del Aguila Pacheco-Cruz; Thalia Belmonte; Francisco J Enguita; Rocío Toro
Journal:  J Mol Med (Berl)       Date:  2021-09-08       Impact factor: 4.599

4.  miR-16-5p Suppression Protects Human Cardiomyocytes against Endoplasmic Reticulum and Oxidative Stress-Induced Injury.

Authors:  Rocío Toro; Alexandra Pérez-Serra; Alipio Mangas; Oscar Campuzano; Georgia Sarquella-Brugada; Maribel Quezada-Feijoo; Mónica Ramos; Martin Alcalá; Esther Carrera; Carlos García-Padilla; Diego Franco; Fernando Bonet
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 5.923

5.  Upregulated miR-328-3p and its high risk in atrial fibrillation: A systematic review and meta-analysis with meta-regression.

Authors:  Haitao Huang; Hao Chen; Xiao Liang; Xiuting Chen; Xiaoxin Chen; Can Chen
Journal:  Medicine (Baltimore)       Date:  2022-03-04       Impact factor: 1.817

6.  A microRNA Signature for the Diagnosis of Statins Intolerance.

Authors:  Alipio Mangas; Alexandra Pérez-Serra; Fernando Bonet; Ovidio Muñiz; Francisco Fuentes; Aurora Gonzalez-Estrada; Oscar Campuzano; Juan Sebastian Rodriguez Roca; Elena Alonso-Villa; Rocio Toro
Journal:  Int J Mol Sci       Date:  2022-07-24       Impact factor: 6.208

Review 7.  A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research.

Authors:  Cameron Brown; Michael Mantzaris; Elpiniki Nicolaou; Georgia Karanasiou; Elisavet Papageorgiou; Giuseppe Curigliano; Daniela Cardinale; Gerasimos Filippatos; Nikolaos Memos; Katerina K Naka; Andri Papakostantinou; Paris Vogazianos; Erietta Ioulianou; Christos Shammas; Anastasia Constantinidou; Federica Tozzi; Dimitrios I Fotiadis; Athos Antoniades
Journal:  Cardiooncology       Date:  2022-09-07

Review 8.  Well-Known and Novel Serum Biomarkers for Risk Stratification of Patients with Non-ischemic Dilated Cardiomyopathy.

Authors:  Larisa Anghel; Radu Sascău; Ioana Mădălina Zota; Cristian Stătescu
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.